Trial Profile
A Randomized, Single Blind, Single Dose, Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Intravenous Dosage Form of LCB01-0371 in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2019
Price :
$35
*
At a glance
- Drugs Delpazolid (Primary) ; Delpazolid
- Indications Methicillin-resistant Staphylococcus aureus infections; Tuberculosis; Vancomycin-resistant enterococcal infections
- Focus Pharmacokinetics
- Sponsors LegoChem Biosciences
- 14 Dec 2018 Results published in the Clinical Therapeutics
- 10 Apr 2018 Status changed from recruiting to completed.
- 10 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.